Kymriah (tisagenlecleucel-T) / University of Pennsylvania, Novartis 
Welcome,         Profile    Billing    Logout  

26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kymriah (tisagenlecleucel-T) / Novartis
NCT04094311: Study of Out of Specification for Tisagenlecleucel

Recruiting
3
200
Canada, Japan
CTL019, Tisagenlecleucel
Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
04/25
04/25
BELINDA, NCT03570892 / 2016-002966-29: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Checkmark From BELINDA trial for 2L DLBCL [Did not met primary end point]
Aug 2021 - Aug 2021: From BELINDA trial for 2L DLBCL [Did not met primary end point]
Active, not recruiting
3
331
Europe, Japan, US, RoW
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
02/26
02/26
LEDA, NCT05888493: A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Recruiting
3
108
Europe, RoW
Tisagenlecleucel, CTL019, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., R2, Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, R-CHOP, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy)
Novartis Pharmaceuticals
Follicular Lymphoma (FL)
07/28
02/29
ELARA, NCT03568461 / 2017-004385-94: Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Checkmark Approved in EU for r/r/ follicular lymphoma based on ELARA study
May 2022 - May 2022: Approved in EU for r/r/ follicular lymphoma based on ELARA study
Checkmark Novartis receives positive CHMP opinion for Kymriah in patients with r/r follicular lymphoma
Mar 2022 - Mar 2022: Novartis receives positive CHMP opinion for Kymriah in patients with r/r follicular lymphoma
Checkmark From ELARA trial for r/r follicular lymphoma at ASCO 2021
More
Active, not recruiting
2
98
Europe, Japan, US, RoW
tisagenlecleucel, CTL019
Novartis Pharmaceuticals
Follicular Lymphoma
11/20
05/25
BIANCA, NCT03610724 / 2017-005019-15: Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Completed
2
34
Europe, Canada, Japan, US, RoW
Tisagenlecleucel, CTL019, lymphodepleting chemotherapy, Bridging Therapy
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
07/21
04/23
2019-002930-35: CAR T cell treatment in Elderly Patients with First-Relapsed or Primary Refractory B-cell Non-Hodgkin Lymphoma

Not yet recruiting
2
28
Europe
Tisagenlecleucel, Injection, Kymriah®
Univeristy of Cologne, Novartis
malignant disease of lymphnodes especially refractory and non-responding aggressive non Hodgkin lymphoma; Diffuse large B cell lymphoma (DLBCL), refractory and non-responding aggressive B-cell Non-Hodgkin’s Lymphoma (aNHL), Diseases [C] - Cancer [C04]
 
 
TIGER, NCT04161118: TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Terminated
2
3
Europe
CTL019
University of Cologne, Novartis
Non Hodgkin Lymphoma
02/23
02/23
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
NCT04276870: Orphan Indications for CD19 Redirected Autologous T Cells

Recruiting
2
81
US
Murine CART19
Stephan Grupp MD PhD, University of Pennsylvania
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
03/28
03/37
REFUEL, NCT05460533: A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Recruiting
2
33
US
Tisagenlecleucel
Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia
07/26
07/26
TARMAC, NCT04234061: Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

Active, not recruiting
2
20
RoW
ibrutinib and Tisagenlecleucel
Peter MacCallum Cancer Centre, Australia, Novartis
Mantle Cell Lymphoma Recurrent
09/27
09/30
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
2021-003035-28: " Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence "CAPTiRALL

Not yet recruiting
1/2
26
Europe
Tisagenleuclecel, Nivolumab, Dispersion for infusion, Concentrate for solution for injection/infusion, Kymriah, OPDIVO
Assistance Publique - Hôpitaux de Paris, DGOS
Relapsed or refractory B-ALL (any relapse after HSCT, 2nd relapse or later, refractory ALL), aged 1-25 years old, previously treated by Tisagenlecleucel (Kymriah ®), Cohort 1 presenting early loss of B cell aplasia (< 6 months after infusion) And being in MRD negative complete remission orCohort 2: presenting loss of B cell aplasia and having detectable marrow and/or blood CD19+ ALL cells., Relapsed or refractory B-ALL, aged 1-25 years old, previously treated by Kymriah ®, Diseases [C] - Cancer [C04]
 
 
CAPTiRALL, NCT05310591: Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

Recruiting
1/2
26
Europe
Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ), Nivolumab starting at day -1
Assistance Publique - Hôpitaux de Paris
B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
03/27
03/27
NCT04855253: Study of E7777 Prior to Kymriah for R/R DLBCL

Recruiting
1/2
30
US
E7777
Masonic Cancer Center, University of Minnesota
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
12/24
12/24
NCT04134117: Tisagenlecleucel In Primary CNS Lymphoma

Active, not recruiting
1
6
US
Tisagenlecleucel, KYMRIAH
Matthew J. Frigault, M.D., Novartis
Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
12/21
12/24
NCT06408194: Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Recruiting
1
20
US
CD22CART infusion, Tisagenlecleucel, KYMRIAH
Stanford University
Leukemia, Acute Lymphoblastic Leukemia
06/25
06/25
NCT04890236: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Recruiting
1
20
US
Duvelisib, 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one, Copiktra, INK-1197, IPI-145, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
Emory University, National Cancer Institute (NCI), Secura Bio, Inc., Novartis
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
08/24
08/25
NCT05075603: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Recruiting
1
57
US
Efineptakin alfa, NT-I7, rhIL-7-hyFc, Tisagenlecleucel, Kymriah, Axicabtagene ciloleucel, Yescarta, Lisocabtagene Maraleucel, Breyanzi
NeoImmuneTech
Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
11/24
02/26
LOKI, NCT06003179: Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah

Recruiting
1
40
Canada
Cyclophosphamide, Cytoxan, neosar, TLI, Fludarabine
University Health Network, Toronto
Lymphoma, Large B-Cell, Diffuse
11/26
11/28
NCT04419909: Retreatment With CTL019/CTL119

Not yet recruiting
1
12
US
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
University of Pennsylvania
Lymphoma, B-Cell
07/27
07/27
NCT06271369: Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.

Completed
N/A
613
US
Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma
02/23
02/23
NCT05199961: Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel

Terminated
N/A
4
US
Digital Health Coaching
Pack Health, Novartis, Ohio State University Comprehensive Cancer Center
Lymphoma, Large B-Cell, Diffuse
09/22
09/22
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients

Available
N/A
Canada, US, RoW
CTL019, tisagenlecleucel, Kymriah
Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
 
 
NCT03642626: MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Active, not recruiting
N/A
144
US
KYMRIAH, tisagenlecleucel, YESCARTA, Fludarabine 30mg/m2 4 doses, Cyclophosphamide 500 mg/m2; 2 doses, Fludarabine 30mg/m2 3 doses, Cyclophosphamide 500 mg/m2; 3 doses, Fludarabine 25mg/m2 3 days, Cyclophosphamide 250 mg/m2; 3 days, Tecartus, Brexucabtagene Autoleucel, Abecma, Intravenous Suspension, Cyclophosphamide 900 mg/m2; 1 day, Breyanzi Injectable Product
Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
02/24
06/28
NCT05541341: Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Recruiting
N/A
200
RoW
tisagenlecleucel
Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Follicular Lymphoma
12/38
12/38

Download Options